FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Thierry Facon, MD, of the University Hospital Hurriez, Lille, France, discusses the updated overall survival analysis of the FIRST study, which compared treatment with continuous lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, and thalidomide (MPT) in patients with newly diagnosed multiple myeloma.

Share this video  
11th June 2015